D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$728M |
| 2 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$625M |
| 3 |
Merck
MRK
|
+$498M |
| 4 |
Bank of America
BAC
|
+$487M |
| 5 |
Fortinet
FTNT
|
+$321M |
Top Sells
| 1 |
Tesla
TSLA
|
+$696M |
| 2 |
Adobe
ADBE
|
+$610M |
| 3 |
Accenture
ACN
|
+$518M |
| 4 |
Microsoft
MSFT
|
+$495M |
| 5 |
Broadcom
AVGO
|
+$471M |
Sector Composition
| 1 | Technology | 22.95% |
| 2 | Consumer Discretionary | 14.11% |
| 3 | Healthcare | 10.4% |
| 4 | Financials | 9.83% |
| 5 | Industrials | 7.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Organogenesis Holdings
ORGO
$625M
| $2.11M | ﹤0.01% |
738,115
-3,818
| -0.5% | -$10.9K |
|
1627
East-West Bancorp
EWBC
$15.1B
| $2.11M | ﹤0.01% |
25,472
-16,747
| -40% | -$1.39M |
|
1628
RAPT Therapeutics
RAPT
$268M
| $2.11M | ﹤0.01% |
131,023
+17,596
| +16% | +$283K |
|
1629
Stoke Therapeutics
STOK
$1.29B
| $2.1M | ﹤0.01% |
171,246
+34,236
| +25% | +$421K |
|
1630
Vera Bradley
VRA
$61.5M
| $2.1M | ﹤0.01% |
384,404
+20,429
| +6% | +$112K |
|
1631
Unifirst Corp
UNF
$3.18B
| $2.09M | ﹤0.01% |
10,538
+2,823
| +37% | +$561K |
|
1632
OceanFirst Financial
OCFC
$1.04B
| $2.09M | ﹤0.01% |
112,345
-120,003
| -52% | -$2.23M |
|
1633
Amalgamated Financial
AMAL
$859M
| $2.09M | ﹤0.01% |
66,478
-33,593
| -34% | -$1.05M |
|
1634
Woodward
WWD
$14.3B
| $2.08M | ﹤0.01% |
12,154
-101,824
| -89% | -$17.5M |
|
|
INVX
1635
Innovex International, Inc.
INVX
$1.14B
| $2.08M | ﹤0.01% |
141,774
-30,709
| -18% | -$451K |
|
1636
SPDR Portfolio S&P 500 Value ETF
SPYV
$28.4B
| $2.08M | ﹤0.01% |
39,325
-56,801
| -59% | -$3M |
|
1637
Honda
HMC
$43.8B
| $2.08M | ﹤0.01% |
+65,501
| New | +$2.08M |
|
|
DX
1638
Dynex Capital
DX
$1.63B
| $2.07M | ﹤0.01% |
162,403
-19,301
| -11% | -$246K |
|
1639
Quanex
NX
$661M
| $2.07M | ﹤0.01% |
74,515
+57,686
| +343% | +$1.6M |
|
1640
BridgeBio Pharma
BBIO
$9.79B
| $2.06M | ﹤0.01% |
80,746
-143,382
| -64% | -$3.65M |
|
1641
Chubb
CB
$111B
| $2.05M | ﹤0.01% |
7,115
-219
| -3% | -$63.2K |
|
1642
ATS Corp
ATS
$2.63B
| $2.05M | ﹤0.01% |
70,589
+18,128
| +35% | +$526K |
|
1643
Applied Optoelectronics
AAOI
$1.69B
| $2.05M | ﹤0.01% |
142,921
-208,051
| -59% | -$2.98M |
|
1644
Royal Gold
RGLD
$12.5B
| $2.04M | ﹤0.01% |
14,558
+11,558
| +385% | +$1.62M |
|
1645
Smith Douglas Homes
SDHC
$993M
| $2.04M | ﹤0.01% |
54,002
+29,031
| +116% | +$1.1M |
|
1646
OptimizeRx
OPRX
$322M
| $2.04M | ﹤0.01% |
263,655
-44,679
| -14% | -$345K |
|
1647
Resources Connection
RGP
$172M
| $2.03M | ﹤0.01% |
209,681
+33,882
| +19% | +$329K |
|
1648
Cadence Design Systems
CDNS
$93.6B
| $2.03M | ﹤0.01% |
7,502
-11,703
| -61% | -$3.17M |
|
1649
Ryder
R
$7.65B
| $2.03M | ﹤0.01% |
13,938
-151
| -1% | -$22K |
|
|
CIO
1650
City Office REIT
CIO
$280M
| $2.03M | ﹤0.01% |
347,904
-110,724
| -24% | -$647K |
|